Spero Therapeutics (SPRO) EBIT Margin (2016 - 2026)
Spero Therapeutics posted quarterly EBIT Margin of 2921.71% for Q1 2026, down 267092.0% year-on-year from N/an in Q1 2025, and down 583.7% on a QoQ basis from 427.34% in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of EBIT Margin data on file, last reported at 2921.71% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 267092.0% year-over-year to 2921.71%; the trailing twelve-month figure through Mar 2026 stood at 107.71% (up 29247.0% YoY), and the FY2025 full-year result was 50.11%, up 20302.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 2921.71%, down from 427.34% in the prior quarter.
- Across five years, EBIT Margin topped out at 159.59% in Q4 2022 and bottomed at 28604.62% in Q3 2024.
- The 5-year median for EBIT Margin is 427.34% (2025), against an average of 2574.96%.
- The widest annual swing landed in 2024, when EBIT Margin sank 2771746 bps; it then jumped 2845915 bps in 2025.
- A 5-year view of EBIT Margin shows it stood at 159.59% in 2022, then sank by 48 bps to 83.08% in 2023, then tumbled by 201 bps to 83.93% in 2024, then plunged by 409 bps to 427.34% in 2025, then plunged by 584 bps to 2921.71% in 2026.
- The last three EBIT Margin figures came in at 2921.71% (Q1 2026), 427.34% (Q4 2025), and 145.46% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | -2,921.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,921.71% |
| Dec 31, 2025 | -427.34% |
| Sep 30, 2025 | -145.46% |
| Jun 30, 2025 | -17.22% |
| Mar 31, 2025 | -250.78% |
| Dec 31, 2024 | -83.93% |
| Sep 30, 2024 | -28,604.62% |
| Jun 30, 2024 | -322.90% |
| Mar 31, 2024 | -150.88% |
| Dec 31, 2023 | 83.08% |
| Sep 30, 2023 | -887.16% |
| Jun 30, 2023 | -474.59% |
| Mar 31, 2023 | -6,379.82% |
| Dec 31, 2022 | 159.59% |
| Sep 30, 2022 | -582.00% |
| Jun 30, 2022 | -1,308.58% |
| Mar 31, 2022 | -1,459.98% |
| Dec 31, 2021 | -178.10% |
| Sep 30, 2021 | -3,181.36% |
| Jun 30, 2021 | -880.44% |
| Mar 31, 2021 | -265.79% |
| Sep 30, 2020 | -50,052.63% |
| Jun 30, 2020 | -1,069.83% |
| Mar 31, 2020 | -1,341.62% |
| Dec 31, 2019 | -3,718.82% |
| Sep 30, 2019 | -387.36% |
| Jun 30, 2019 | -20,376.12% |
| Mar 31, 2019 | -73.80% |
| Dec 31, 2018 | -655.08% |
| Sep 30, 2018 | -1,661.85% |
| Jun 30, 2018 | -2,153.56% |
| Dec 31, 2017 | -1,409.87% |
| Sep 30, 2017 | -1,669.35% |
| Jun 30, 2017 | -4,082.33% |
| Mar 31, 2017 | -5,427.86% |
| Dec 31, 2016 | 13,553.85% |
| Sep 30, 2016 | -7,914.00% |